PuSH - Publikationsserver des Helmholtz Zentrums München

Saxagliptin, alogliptin, and cardiovascular outcomes.

N. Engl. J. Med. 370, 483-484 (2014)
DOI
To the Editor: Besides showing futility in the use of dipeptidyl peptidase 4 (DPP-4) inhibitors to reduce cardiovascular outcomes, the studies by Scirica et al.(1) and White et al.(2) (Oct. 3 issue) have raised concerns regarding increased rates of heart failure associated with these agents. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 (SAVOR-TIMI 53) trial, reported by Scirica et al., showed a 27% increase in hospitalization for heart failure among patients with diabetes who received saxagliptin as compared with patients with diabetes who received placebo (3.5% vs. 2.8%; hazard ...
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Letter to the Editor
ISSN (print) / ISBN 0028-4793
e-ISSN 1533-4406
Quellenangaben Band: 370, Heft: 5, Seiten: 483-484 Artikelnummer: , Supplement: ,
Verlag Massachusetts Medical Society (MMS)
Verlagsort Waltham
Begutachtungsstatus Peer reviewed